Actively Recruiting

Age: 6Years +
All Genders
ID04557969

Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Led by National Cancer Institute (NCI) · Updated on 2026-06-05

400

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate and follow people with gastrointestinal stromal tumors (GISTs), focusing on those with wild-type (WT) and treatment-resistant types. GISTs are rare soft tissue sarcomas often characterized by specific genetic mutations. Since many GISTs may become resistant to current drug therapies, surgical removal remains the main treatment, and this study supports research to better understand and develop new treatment options for these tumors. Participants with confirmed or suspected GIST will be monitored closely over long periods. Those suitable will be offered surgery to remove tumors, while others will be under active surveillance. The study includes up to 10 years of monitoring before surgery and up to 5 years after surgery, with the possibility of multiple surgeries and renewed monitoring periods. Tumor tissue samples will be collected during surgery to support laboratory research and genomic analysis. Participants will have regular medical history reviews, physical exams, and evaluations of daily functioning. They may undergo genetic counseling and testing, blood draws, cheek swabs, and imaging scans like CT or MRI. Monitoring visits will occur every 6 to 12 months, lasting up to 15 years depending on surgeries and follow-up. Researchers will assess disease-free intervals between surgeries and characterize tumor features over time to better understand GIST progression and outcomes.

CONDITIONS

Brief Title

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Who Can Participate

Age: 6Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological confirmation or clinical presentation suspicious of GIST
  • Age 6 years or older
  • ECOG performance status 2 or lower (Karnofsky or Lansky 60% or higher)
  • Ability to understand and willingness to sign informed consent (participant or parent/guardian)
Not Eligible

You will not qualify if you...

  • Non-modifiable medical conditions that would prevent cytoreductive surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 10 years before and 5 years after surgery

Participants with histologically confirmed or suspicious GIST are actively monitored with visits every 9 to 15 months to assess disease status before and after surgical interventions.

Visits every 9 to 15 months

Surgery and Immediate Post-operative Care

Duration - Variable, depending on individual surgical procedures

Participants who undergo surgical resection or cytoreduction of GIST tissue receive surgery and immediate post-operative care as clinically indicated.

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

S

Stephanie N Canady, R.N.

A

Andrew M Blakely, M.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

Clinical Outcomes of Indocyanine Green Tracer in 3D Plus Ult...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here